TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data

Central Nervous System Tumors

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas

Eur J Cancer.

Franceschi E, Tosoni A, Bartolini S, Minichillo S, Mura A, Asioli S, Bartolini D, Gardiman M, Gessi M, Ghimenton C, Giangaspero F, Lanza G, Marucci G, Novello M, Silini EM, Zunarelli E, Paccapelo A, Brandes AA

doi: 10.1016/j.ejca.2020.06.018.

Breast Cancer

Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis

J Natl Cancer Inst.

Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D

doi: 10.1093/jnci/djaa071.

Central Nervous System Tumors

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials

Eur J Cancer.

Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB, EORTC Quality of Life Group and the EORTC Brain Tumor Group.

doi: 10.1016/j.ejca.2019.05.012.

Central Nervous System Tumors

Correlation of immune phenotype with IDH mutation in diffuse glioma

Neuro Oncol.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M

doi: 10.1093/neuonc/nox054.

Lymphoma

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis

Eur J Cancer.

Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O

doi: 10.1016/j.ejca.2017.01.021.

RECOMMENDED

Breast Cancer

ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Clin Cancer Res.

Turner NC, Swift C, Kilburn LS, Fribbens C, Beaney M, Garcia-Murillas I, Buzdar AU, Roberston JF, Gradishar W, Piccart M, Schiavon G, Bliss JM, Dowsett M, Johnston SRD, Chia SK

doi: 10.1158/1078-0432.CCR-20-0224.

RECOMMENDED

Genitourinary CancerRadio-Oncology

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis

JAMA Oncol.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR

doi: 10.1001/jamaoncol.2018.3732.

Gynecologic Cancer

BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis

J Natl Cancer Inst.

Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, Lu KH, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT

doi: 10.1093/jnci/djaa070.

Central Nervous System Tumors

Arterial Spin Labeling MR imaging for differentiation between high and low grade glioma - a meta-analysis

Neuro Oncol.

Falk Delgado A, De Luca F, van Westen D, Falk Delgado A

doi: 10.1093/neuonc/noy095.

Related content

Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas

Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials

Correlation of immune phenotype with IDH mutation in diffuse glioma

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis

ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis

BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis

Arterial Spin Labeling MR imaging for differentiation between high and low grade glioma - a meta-analysis